MX386342B - Móleculas de unión a her2 y cd3 biespecíficas. - Google Patents

Móleculas de unión a her2 y cd3 biespecíficas.

Info

Publication number
MX386342B
MX386342B MX2017001031A MX2017001031A MX386342B MX 386342 B MX386342 B MX 386342B MX 2017001031 A MX2017001031 A MX 2017001031A MX 2017001031 A MX2017001031 A MX 2017001031A MX 386342 B MX386342 B MX 386342B
Authority
MX
Mexico
Prior art keywords
binding molecules
her2
bispecific her2
managing
methods
Prior art date
Application number
MX2017001031A
Other languages
English (en)
Spanish (es)
Other versions
MX2017001031A (es
Inventor
Andres Lopez-Albaitero
Hong Xu
Nai- Kong V Cheung
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017001031A publication Critical patent/MX2017001031A/es
Publication of MX386342B publication Critical patent/MX386342B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2017001031A 2014-07-25 2015-07-24 Móleculas de unión a her2 y cd3 biespecíficas. MX386342B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029342P 2014-07-25 2014-07-25
PCT/US2015/041989 WO2016014942A1 (en) 2014-07-25 2015-07-24 Bispecific her2 and cd3 binding molecules

Publications (2)

Publication Number Publication Date
MX2017001031A MX2017001031A (es) 2017-05-04
MX386342B true MX386342B (es) 2025-03-18

Family

ID=53836217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001031A MX386342B (es) 2014-07-25 2015-07-24 Móleculas de unión a her2 y cd3 biespecíficas.

Country Status (15)

Country Link
US (2) US10519248B2 (index.php)
EP (1) EP3172236B1 (index.php)
JP (1) JP6871155B2 (index.php)
KR (1) KR102638104B1 (index.php)
CN (1) CN107124884B (index.php)
AU (1) AU2015292374B2 (index.php)
BR (1) BR112017001513A2 (index.php)
CA (1) CA2956014C (index.php)
ES (1) ES2832704T3 (index.php)
IL (1) IL250249B (index.php)
MX (1) MX386342B (index.php)
RU (1) RU2017105849A (index.php)
SG (1) SG11201700506TA (index.php)
WO (1) WO2016014942A1 (index.php)
ZA (1) ZA201701341B (index.php)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240939T1 (hr) 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
CA2956014C (en) 2014-07-25 2023-10-31 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN109923128A (zh) 2016-11-15 2019-06-21 基因泰克公司 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EP3574012A1 (en) * 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
US11529371B2 (en) 2017-04-24 2022-12-20 Memorial Sloan Kettering Cancer Center Anti-CD33 antibody agents
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
EP3749361A1 (en) 2018-02-08 2020-12-16 F. Hoffmann-La Roche AG Bispecific antigen-binding molecules and methods of use
US20210017295A1 (en) * 2018-03-12 2021-01-21 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
CN111566127B (zh) * 2018-03-27 2024-06-07 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
AR114284A1 (es) * 2018-04-13 2020-08-12 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CA3103414A1 (en) 2018-06-14 2019-12-19 Bioatla, Inc. Multi-specific antibody constructs
EP3889179A4 (en) * 2018-11-01 2022-10-12 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
WO2020113164A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
EP3894601A4 (en) * 2018-12-11 2023-01-11 The Translational Genomics Research Institute IDENTIFICATION OF HER2 MUTATIONS IN LUNG CANCER AND METHODS OF TREATMENT
KR20210142628A (ko) * 2019-02-22 2021-11-25 메모리얼 슬로안 케터링 캔서 센터 Cd33 항체 및 이를 사용하여 암을 치료하는 방법
WO2020210232A1 (en) * 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CA3139111A1 (en) * 2019-05-23 2020-11-26 VelosBio Inc. Anti-ror1/anti-cd3 bispecific binding molecules
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022026439A2 (en) * 2020-07-28 2022-02-03 Memorial Sloan Kettering Cancer Center Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
US20230374150A1 (en) * 2020-10-12 2023-11-23 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
IL302217A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
EP4240492A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4255922A1 (en) 2020-12-03 2023-10-11 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
CA3228259A1 (en) * 2021-08-04 2023-02-09 Abpro Corporation Anti-her2 antibodies and uses thereof
EP4419567A4 (en) * 2021-10-20 2025-09-17 Memorial Sloan Kettering Cancer Center MULTI-SPECIFIC ANTI-TSHR ANTIBODIES AND THEIR USES
KR102803655B1 (ko) 2021-12-29 2025-05-08 건국대학교 글로컬산학협력단 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR102857671B1 (ko) 2021-12-29 2025-09-10 건국대학교 글로컬산학협력단 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
TWI874962B (zh) 2022-04-13 2025-03-01 美商建南德克公司 莫蘇妥珠單抗之醫藥組成物及其使用方法
AU2024214000A1 (en) * 2023-02-04 2025-08-21 Imagion Biosystems, Inc. Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
FI2155783T4 (fi) 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
US8648176B2 (en) 2009-02-27 2014-02-11 Massachusetts Institute Of Technology Engineered proteins with high affinity for DOTA chelates
JP6320753B2 (ja) 2010-05-27 2018-05-09 ゲンマブ エー／エス Ｈｅｒ２に対するモノクローナル抗体
US9315585B2 (en) * 2010-06-19 2016-04-19 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
SG194875A1 (en) * 2011-05-08 2013-12-30 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
JP6020581B2 (ja) * 2011-11-02 2016-11-02 味の素株式会社 タンパク質の分泌生産法
EP2895203A4 (en) * 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
WO2014079000A1 (en) 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
DK3024851T3 (en) * 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
CN112353943A (zh) 2013-12-17 2021-02-12 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
CA2956014C (en) 2014-07-25 2023-10-31 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules

Also Published As

Publication number Publication date
NZ729286A (en) 2023-12-22
EP3172236A1 (en) 2017-05-31
EP3172236B1 (en) 2020-09-30
WO2016014942A1 (en) 2016-01-28
AU2015292374B2 (en) 2020-09-03
JP6871155B2 (ja) 2021-05-12
US10519248B2 (en) 2019-12-31
AU2015292374A1 (en) 2017-03-16
US20200199248A1 (en) 2020-06-25
KR20170038835A (ko) 2017-04-07
JP2017527274A (ja) 2017-09-21
ZA201701341B (en) 2021-05-26
CA2956014A1 (en) 2016-01-28
CN107124884A (zh) 2017-09-01
KR102638104B1 (ko) 2024-02-20
IL250249B (en) 2021-04-29
MX2017001031A (es) 2017-05-04
US20170210819A1 (en) 2017-07-27
SG11201700506TA (en) 2017-02-27
ES2832704T3 (es) 2021-06-11
BR112017001513A2 (pt) 2018-02-14
IL250249A0 (en) 2017-03-30
US11987642B2 (en) 2024-05-21
CA2956014C (en) 2023-10-31
CN107124884B (zh) 2022-11-01
RU2017105849A (ru) 2018-08-29

Similar Documents

Publication Publication Date Title
MX386342B (es) Móleculas de unión a her2 y cd3 biespecíficas.
MX2020006668A (es) Anticuerpos para lilrb2.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
MX2015007189A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
PH12017501748B1 (en) Antibodies to icos
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
JO3740B1 (ar) روابط pd1/ctla4
MX2015013163A (es) Complejos multiespecificos multivalente y monovalentes y sus usos.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2017005553A (es) Terapia de combinacion para cancer.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
WO2017035430A3 (en) Anti-alk antibodies and methods for use thereof
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
EA201591709A1 (ru) 5-бром-индирубины
EA201792249A1 (ru) Комбинированная терапия злокачественной опухоли